Pharmacokinetic assessment of ketanserin in the horse

PHARMACOKINETIC STUDY OF ORAL ε-AMINOCAPROIC ACID IN THE NORTHERN ELEPHANT SEAL (MIROUNGA ANGUSTIROSTRIS)

ε-Aminocaproic acid (EACA) is a lysine analogue antifibrinolytic drug used to treat bleeding disorders in humans and domestic animals. Its use in zoological medicine is rare, and dosage is anecdotal. One possible application of EACA is to treat bleeding associated with prepatent Otostrongylus arteritis in Northern elephant seals ( Mirounga angustirostris ) presenting to wildlife rehabilitation centers. This study used an in vitro model of hyperfibrinolysis and a thromboelastograph-based assay to estimate the therapeutic plasma concentration of EACA in elephant seals (85 μg/ml, 95% confidence interval = 73.8-96.8 μg/ml). A concurrent pharmacokinetic study of orally administered, single-dose EACA found that doses of 75 and 100 mg/kg achieved therapeutic plasma concentrations (>85 μg/ml), but the drug was rapidly eliminated and remained in the therapeutic range for only 0.4 and 1.5 hr, respectively. Models of repeated oral dosing at 100 mg/kg every 6 hr predict that therapeutic plasma concentration will be maintained for 31.7% (7.6 hr) of a 24-hr period. More frequent dosing would be required to maintain continuous therapeutic concentrations but would be impractical in a wildlife rehabilitation setting. Further pharmacodynamic studies to evaluate the duration of action of EACA in elephant seals and a prospective, placebo-controlled study are needed to determine if EACA is effective in decreasing bleeding associated with prepatent Otostrongylus arteritis and other bleeding disorders in this species.

[New drugs for horses and production animals in 2015]

In 2015, four newly developed active pharmaceutical ingredients for horses and food-producing animals were released on the German market for veterinary drug products. These were the bisphosphonate Clodronic Acid (Osphos®), the 5-hydroxytryptamine (2A) receptor antagonist Ketanserin (Vulketan®), the aminoglycoside antibiotic Paromomycin (Parofor®) and the antibiotic Thiamphenicol (TAF Spray®) from the fenicole group. With Chlorphenamine, a temporary not available active ingredient was reapproved in a new drug. Furthermore, three veterinary drugs with a new formulation as well as one product with a new strength and two products with a new combination of active pharmaceutical ingredients have been launched.